MAGE and Glucose Variability

By Web Admin
Medical Disclaimer

This article is for informational purposes only and does not constitute medical advice. Always consult your physician or a qualified healthcare provider regarding any medical condition or treatment.

Key Takeaways

  • MAGE (Mean Amplitude of Glycemic Excursions) is the average of glucose swings (peak to nadir or nadir to peak) that exceed 1 standard deviation — originally defined by Service and colleagues in 1970.
  • MAGE captures large postprandial spikes and nocturnal dips that smaller variability metrics may smooth over.
  • A rough target is MAGE less than 60 mg/dL; lower is better. Type 1 diabetes typically runs higher; non-diabetic adults run well below 60.
  • MAGE is more cumbersome to calculate than CV and is less commonly displayed by CGM software — but it correlates with hypoglycemia, oxidative stress markers, and complications in research settings.
  • Other variability metrics (CV, SD, MODD, iAUC) complement MAGE — use them together rather than relying on a single number.
Table of Contents
  1. How MAGE Is Calculated
  2. Worked Example
  3. MAGE Targets by Population
  4. MAGE vs Other Variability Metrics
  5. Why Variability Matters
  6. What Drives High MAGE
  7. Strategies to Lower MAGE
  8. When MAGE Is Most Useful
  9. Limitations of MAGE
  10. Putting It All Together
  11. Related Reading
  12. The Bottom Line

MAGE (Mean Amplitude of Glycemic Excursions) is a glucose variability metric that averages the magnitude of swings exceeding 1 standard deviation. Defined by Service and colleagues in 1970, it captures the large postprandial spikes and nocturnal dips that matter physiologically. Rough clinical target is less than 60 mg/dL.

How MAGE Is Calculated

  1. Collect CGM glucose data over at least 24 hours (typically 14 days).
  2. Calculate the standard deviation (SD) of all readings.
  3. Identify all peak-to-nadir or nadir-to-peak excursions within the data.
  4. Keep only excursions whose magnitude exceeds 1 SD.
  5. Average those magnitudes — that average is MAGE.
  6. Direction: by convention, MAGE is calculated from the first direction encountered (peak then nadir, or vice versa).

The 1-SD filter is what gives MAGE its character. Small wiggles in glucose are ignored; only meaningful excursions count.

Worked Example

Time Glucose (mg/dL) Excursion (mg/dL) Exceeds 1 SD?
6 AM 120 — —
9 AM 210 (peak) +90 Yes
11 AM 140 (nadir) −70 Yes
1 PM 175 (peak) +35 No
3 PM 155 −20 No
7 PM 250 (peak) +95 Yes
11 PM 130 (nadir) −120 Yes
3 AM 65 (nadir) −65 Yes
6 AM 150 (peak) +85 Yes

Average of the qualifying excursions (90, 70, 95, 120, 65, 85) = approximately 88 mg/dL. That is the MAGE for this 24-hour window. For multi-day windows, the same calculation extends across all days.

MAGE Targets by Population

Population Typical MAGE Range (mg/dL)
Non-diabetic adults 10 to 30
Type 2 diabetes, non-insulin therapy, well controlled 40 to 70
Type 2 diabetes, basal insulin 60 to 90
Type 2 diabetes, basal-bolus insulin 70 to 110
Type 1 diabetes, multiple daily injections 80 to 140
Type 1 diabetes, automated insulin delivery 60 to 100
Pregnancy with diabetes (tight target) 40 to 70 ideal

MAGE vs Other Variability Metrics

Metric What It Captures Reported by CGM Software?
SD Absolute spread of all readings Yes
CV SD normalized to mean Yes
MAGE Average magnitude of large swings (>1 SD) Usually not
MODD Mean of daily differences at same time of day Sometimes
iAUC Incremental area under curve (postprandial) Research mostly
CONGA Continuous overlapping net glycemic action Research only

MAGE is more sensitive to discrete large excursions than CV. For day-to-day stability across the same time of day, MODD is more informative. For the routine clinical scorecard, CV and TIR are easier and usually adequate. For a deeper comparison, see coefficient of variation for glucose.

Why Variability Matters

  • Oxidative stress: rapid glucose swings generate more reactive oxygen species than steady hyperglycemia in cell and animal models.
  • Endothelial dysfunction: the vascular lining is damaged by acute glucose changes.
  • Inflammation: markers like IL-6 and TNF-alpha rise with high variability.
  • Hypoglycemia risk: larger excursions mean both more highs and more lows.
  • Cognitive symptoms: rapid drops cause shakiness, fatigue, and “brain fog.”
  • Quality of life: high-variability days feel worse than steady moderate hyperglycemia.
  • Possible complications independence: evidence is mixed; some studies show variability adds to A1C in predicting microvascular disease.

What Drives High MAGE

  • Large carbohydrate meals — especially high-glycemic-index carbs.
  • Insulin timing errors (taking insulin after eating instead of 15 min before).
  • Carb counting inaccuracies.
  • Gastroparesis — delayed and variable absorption.
  • Skipped or mistimed basal insulin.
  • Overcorrection of highs (large doses creating overshoot).
  • Alcohol — late-night liver glucose effects.
  • Exercise without dose adjustment.
  • Stress and acute illness.
  • Hormonal cycles, including menstruation and steroid pulses.

Strategies to Lower MAGE

  • Smaller, more frequent meals: smaller carb amounts produce smaller spikes.
  • Lower-GI carbs: swap white rice for basmati or quinoa; swap white bread for sourdough or whole grain.
  • Pre-meal insulin timing: dosing 15 minutes before high-GI meals can cut peak by 30 to 50 mg/dL.
  • Protein and fat before carbs: eat the salad and protein first.
  • Vinegar with meals: see our apple cider vinegar guide.
  • Post-meal walk: 10 to 20 minutes blunts the peak by 20 to 30 percent.
  • Automated insulin delivery: AID systems typically cut MAGE by 20 to 40 mg/dL.
  • Eliminate overcorrection: stack-avoidance, conservative correction doses.
  • Address gastroparesis: medication review, meal modifications, possibly prokinetic agents.

When MAGE Is Most Useful

  • Research studies — comparing variability between interventions.
  • Cases of unexplained hypoglycemia despite acceptable A1C.
  • Suspected brittle diabetes.
  • Postprandial-pattern troubleshooting.
  • Comparing insulin regimens (e.g., NPH vs glargine).
  • Evaluating AID system effectiveness.
  • Pregnancy where tight control is needed.

Limitations of MAGE

  • Computationally cumbersome compared to SD or CV.
  • Sensitive to definition (1 SD threshold, peak/nadir convention).
  • Not consistently reported across CGM platforms.
  • Highly dependent on data window length.
  • Sensor noise can inflate values.
  • Less validated for type 2 diabetes than for type 1.
  • Hard to compare across studies that use different calculation methods.

Putting It All Together

Pattern Suggested Metrics
Routine clinical follow-up A1C, TIR, GMI, CV
Hypoglycemia investigation TBR, CV, MAGE
Postprandial troubleshooting iAUC, MAGE, AGP modal day
Day-to-day stability MODD
Overall variability snapshot CV plus MAGE

See Time in Range, GMI vs A1C, coefficient of variation for glucose, and Ambulatory Glucose Profile.

The Bottom Line

MAGE captures glucose variability by averaging the magnitude of swings exceeding 1 standard deviation. Rough target less than 60 mg/dL. It is less commonly reported than CV but adds value when postprandial spikes and nocturnal dips are the clinical concern. Use MAGE alongside CV, TIR, and TBR rather than alone. Lower MAGE through pre-meal insulin timing, lower-GI carbs, post-meal walking, smaller carb portions, and automated insulin delivery. The biggest single lever for most people is meal timing and content.

Frequently Asked Questions

What is a good MAGE value?

A rough clinical target is MAGE less than 60 mg/dL. Non-diabetic adults typically have MAGE under 30 mg/dL. People with well-controlled type 2 diabetes on non-insulin therapy often run MAGE of 40 to 70 mg/dL. Type 1 diabetes and insulin-treated type 2 diabetes typically run MAGE of 60 to 120 mg/dL. MAGE above 100 mg/dL suggests significant variability and warrants review.

How is MAGE different from coefficient of variation?

CV is a normalized measure of overall spread (SD divided by mean, times 100). MAGE specifically captures the magnitude of large excursions that exceed 1 SD — the spikes and dips that matter most physiologically. Two CGM profiles with the same CV can have different MAGE if one has rare large swings and the other has many small swings. MAGE is more sensitive to postprandial spikes; CV is more sensitive to overall stability.

Is MAGE shown in my CGM app?

Usually not by default. Dexcom Clarity, FreeStyle LibreView, and most commercial CGM apps report CV, SD, TIR, GMI, and percentiles — but not MAGE. MAGE is more common in research settings or with dedicated CGM analytics platforms. Some clinicians calculate it manually from CGM exports. The omission reflects MAGE's computational complexity, not its clinical irrelevance.

Does lowering MAGE improve diabetes outcomes?

Evidence is moderate, not definitive. Lower MAGE correlates with lower oxidative stress markers, less hypoglycemia, and better quality of life. Whether MAGE-targeted interventions reduce complications independently of A1C is still debated. Most clinicians treat MAGE as one of several variability indicators rather than a standalone target. Lower variability is generally beneficial; how much benefit comes from MAGE specifically versus the means of achieving lower variability is unresolved.

Sources

  1. Service FJ, et al. Mean Amplitude of Glycemic Excursions, a Measure of Diabetic Instability. Diabetes 19(9):644-655, 1970.
  2. Battelino T, et al. Clinical Targets for Continuous Glucose Monitoring Data Interpretation. Diabetes Care 42(8):1593-1603, 2019.
  3. American Diabetes Association. Standards of Care in Diabetes 2024. Diabetes Care 47(Suppl 1).

Related Articles